AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer

AtaiBeckley shares surged following reports that Eli Lilly is positioned to acquire the psychedelic drug developer. The deal, which marks Lilly's entry into the psychedelic drug race, is valued at up to $3.8 billion. This strategic move allows Lilly to expand its portfolio into the psychedelic space by leveraging AtaiBeckley's specialized development capabilities. The market reacted positively to the news of the potential acquisition, driving a significant increase in the developer's stock price.